/C O R R E C T I O N — Moleculin Biotech, Inc./

In the news release, Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting, issued 08-Apr-2022 by Moleculin Biotech, Inc. over PR Newswire, we are advised by the company that the second paragraph following the details section, third sentence, should read “Median survival in the group receiving 6 mg/kg Annamycin was 2.72 fold higher than vehicle [median survival (MS) 79d for treated vs 29d vehicle, p<0.0001] and 2.34 fold higher than vehicle for the animals dosed with Annamycin at 4 mg/kg [MS 68d, p=0.0012].” rather than “The delay correlated with 272% extension of survival in the group receiving 6 mg/kg Annamycin [median survival (MS) 79d for treated vs 29d vehicle, p<0.0001] and 234% for the animals dosed with Annamycin at 4 mg/kg [MS 68d, p=0.0012].” as originally issued inadvertently. The complete, corrected release follows: Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting Annamycin exhibited robust antitumor activity in experimental colorectal cancer liver and lung metastasis models Results support advancement of preclinical development toward initiating clinical studies in metastatic colorectal cancer patients HOUSTON, April 8, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that preclinical data of Annamycin tested in syngeneic models of metastatic colorectal cancer established in lungs or liver was accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held April 8-13, 2022, in New Orleans, Louisiana.

The release as fetched from its publisher. moleculin.com ↗